<DOC>
	<DOCNO>NCT00048308</DOCNO>
	<brief_summary>During heart bypass procedure , substance call `` complement '' release body . This complement cause inflammation , lead side effect chest pain , heart attack , heart failure , impairment memory , language motor skill . The purpose study find study drug ( pexelizumab ) , block complement release , reduce side effect take safely .</brief_summary>
	<brief_title>Effect Pexelizumab All-Cause Mortality Myocardial Infarction Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA : The study population drawn patient undergo CABG CABG plus valve surgery use bypass pump . In addition , must meet following criterion : least 18 year age ; one follow risk factor : diabetes mellitus ; prior CABG ; need urgent intervention , define accord American College Cardiology/ American Heart Association ( ACC/AHA ) guideline patient require stay hospital , may schedule operate within normal schedule routine , exclude patient MI within 48 hour CABG ; female ; history neurologic event ( cerebrovascular accident , transient ischemic attack carotid endarterectomy ) ; history congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) ; history 2 myocardial infarction , myocardial infarction occur great 48 hour less four ( 4 ) week prior CABG ; provide Informed Consent . EXCLUSION CRITERIA : A patient ineligible study entry he/she meet follow exclusion criterion : plan aortic dissection repair and/or require aortic root reconstruction ; require salvage intervention define ACC/AHA guideline ongoing cardiopulmonary resuscitation way operate room ; current cardiogenic shock , acute leave ventricular rupture , acute septal rupture acute papillary muscle rupture ; uncontrolled diabetes , define document plasma blood glucose value &gt; 400 mg/dl ( 22.2 mmol/L ) within three ( 3 ) day surgery ; history renal failure serum creatinine value great 3.0 mg/dl ; history chronic hepatic failure and/or hepatic cirrhosis ; history malignancy , except basal cell carcinoma malignancy remission ( great 2 year ) ; active bacterial infection clinically significant , opinion investigator ( e.g . evaluate evidence base WBC , temperature , culture , etc . appropriate patient ) ; serious medical condition , opinion investigator likely alter patient 's course recovery evaluation study medication 's safety ; history alcohol drug abuse within past year ; know suspect hereditary complement deficiency ; participate investigational drug study expose investigational agent device within 30 day randomization ; receiving , plan receive , investigational drug device , participate research study trial ; pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CABG</keyword>
</DOC>